World Library  
Flag as Inappropriate
Email this Article

Resiquimod

Article Id: WHEBN0022648401
Reproduction Date:

Title: Resiquimod  
Author: World Heritage Encyclopedia
Language: English
Subject: Edoxudine, Purine analogue, Thymidine kinase from herpesvirus, Clevudine, Fomivirsen
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Resiquimod

Resiquimod
Systematic (IUPAC) name
1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
Clinical data
Legal status
  • Investigational
Routes Topical
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  N
UNII  N
ChEMBL  N
Chemical data
Formula C17H22N4O2 
Mol. mass 314.382 g/mol
 N   

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical cream in the treatment of skin lesions[1] such as those caused by the herpes simplex virus,[2][3] and as an adjuvant to increase the effectiveness of vaccines.[4] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,[5] and an upregulator of the opioid growth factor receptor.[6]

See also

References

  1. ^ Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (July 2008). "A phase II dose-ranging study of topical resiquimod to treat actinic keratosis". The British Journal of Dermatology 159 (1): 205–10.  
  2. ^ Wu JJ, Huang DB, Tyring SK (November 2004). "Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses". Antiviral Research 64 (2): 79–83.  
  3. ^ Fife KH, Meng TC, Ferris DG, Liu P (February 2008). "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions". Antimicrobial Agents and Chemotherapy 52 (2): 477–82.  
  4. ^ Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (October 2007). "Resiquimod and other immune response modifiers as vaccine adjuvants". Expert Review of Vaccines 6 (5): 835–47.  
  5. ^ Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (February 2009). "TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells". Immunobiology 214 (8): 683–91.  
  6. ^ Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (August 2008). "Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function". Experimental Biology and Medicine (Maywood, N.J.) 233 (8): 968–79.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.